{"id":3288,"date":"2016-10-14T12:12:16","date_gmt":"2016-10-14T11:12:16","guid":{"rendered":"http:\/\/www2.imperial.ac.uk\/fom\/?p=3288"},"modified":"2016-11-01T15:10:47","modified_gmt":"2016-11-01T14:10:47","slug":"apollo-therapeutics-launch","status":"publish","type":"post","link":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/2016\/10\/14\/apollo-therapeutics-launch\/","title":{"rendered":"Apollo Therapeutics launch"},"content":{"rendered":"<p class=\"p1\"><span class=\"s1\">The official Imperial launch of the Apollo Therapeutics took place on 6<\/span><span class=\"s1\">\u00a0October.\u00a0 Apollo Therapeutics is a collaboration between three global pharmaceutical companies (GSK, J&amp;J and AZ) and three Universities \u2013 Imperial, Cambridge and UCL.\u00a0 This is the first time that three global pharmaceutical companies and the tech transfer offices of three world leading universities has come together to form a joint enterprise resulting in a truly innovative venture <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" class=\"alignright wp-image-3290\" src=\"https:\/\/blogs-staging.imperial.ac.uk\/fom\/files\/2016\/11\/James-Sterling-speaking-2-300x300.jpeg\" alt=\"james-sterling-speaking-2\" \/>aimed driving forward therapeutic innovation.\u00a0 It is a \u00a340 million fund to drive therapeutic innovation aims to to significantly improve the speed and potential of university research being translated into novel medicines. Apollo will support translational research, shaping projects at an early stage to optimise discovery and delivery of new breakthrough treatments for onward development.<\/span><span class=\"s1\">\u00a0<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">The launch event saw more than 75 Imperial academics, industry collaborators and Apollo representatives coming tog ether.\u00a0 The event was opened by Professor James Stirling and the scheme was introduced by Ian Tomlinson (Apollo Therapeutics Chairman) and Richard Butt (Apollo Therapeutics CEO).\u00a0 A panel Q&amp;A session with The Apollo Leadership team together with Professor Jonathan Weber and Dr Mene Pangalos (<\/span><span class=\"s3\">\u200e<\/span><span class=\"s1\">Executive Vice President at AstraZeneca) discussed the opportunities for the College presented by the venture.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">A call for biologics proposals is currently open; for more information about the scheme please see: <a href=\"http:\/\/apollotherapeutics.com\/\"><span class=\"s4\">http:\/\/apollotherapeutics.com\/<\/span><\/a><\/span><\/p>\n<p class=\"p1\"><strong>Dr Sarah Wagstaffe<\/strong><br \/>\n<strong>Head of Research Strategy<\/strong><br \/>\n<strong>Faculty of Medicine<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The official Imperial launch of the Apollo Therapeutics took place on 6\u00a0October.\u00a0 Apollo Therapeutics is a collaboration between three global pharmaceutical companies (GSK, J&amp;J and AZ) and three Universities \u2013 Imperial, Cambridge and UCL.\u00a0 This is the first time that three global pharmaceutical companies and the tech transfer offices of three world leading universities has [&hellip;]<\/p>\n","protected":false},"author":777,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16283,53],"tags":[],"class_list":["post-3288","post","type-post","status-publish","format-standard","hentry","category-corporate-and-enterprise-partnerships","category-events"],"_links":{"self":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/posts\/3288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/users\/777"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/comments?post=3288"}],"version-history":[{"count":1,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/posts\/3288\/revisions"}],"predecessor-version":[{"id":3291,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/posts\/3288\/revisions\/3291"}],"wp:attachment":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/media?parent=3288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/categories?post=3288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/fom\/wp-json\/wp\/v2\/tags?post=3288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}